Jeff Yass’s Tango Therapeutics TNGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.31M Buy
105,985
+19,635
+23% +$485K ﹤0.01% 5421
2026
Q1
$1.81M Buy
86,350
+51,134
+145% +$712K ﹤0.01% 6406
2025
Q4
$312K Sell
35,216
-53,623
-60% -$462K ﹤0.01% 9850
2025
Q3
$746K Sell
88,839
-153,608
-63% -$1.04M ﹤0.01% 8046
2025
Q2
$1.24M Buy
242,447
+175,832
+264% +$435K ﹤0.01% 6886
2025
Q1
$91.3K Buy
66,615
+41,342
+164% +$102K ﹤0.01% 11595
2024
Q4
$78.1K Buy
25,273
+8,965
+55% +$41.6K ﹤0.01% 11482
2024
Q3
$126K Buy
16,308
+1,478
+10% +$14.1K ﹤0.01% 10892
2024
Q2
$127K Sell
14,830
-28,062
-65% -$217K ﹤0.01% 10849
2024
Q1
$341K Buy
42,892
+16,476
+62% +$177K ﹤0.01% 9419
2023
Q4
$262K Buy
26,416
+1,578
+6% +$13.7K ﹤0.01% 10118
2023
Q3
$280K Buy
24,838
+9,190
+59% +$56K ﹤0.01% 9507
2023
Q2
$52K Sell
15,648
-12,446
-44% -$44.8K ﹤0.01% 11327
2023
Q1
$111K Buy
+28,094
New +$163K ﹤0.01% 11205
2022
Q4
Sell
-13,480
Closed -$49K 13678
2022
Q3
$49K Buy
+13,480
New +$57.6K ﹤0.01% 12221
2022
Q2
Sell
-332,000
Closed -$2.52M 13948
2022
Q1
$2.52M Buy
332,000
+215,120
+184% +$1.86M ﹤0.01% 4966
2021
Q4
$1.28M Buy
+116,880
New +$1.41M ﹤0.01% 6616

Other funds holding TNGX

Jeff Yass's TNGX Position: Q2 2026 in Review

Jeff Yass increased its Tango Therapeutics (TNGX) stake by 23% in Q2 2026, buying an estimated $485K and bringing the position to 105,985 shares worth $3.31M. The position accounts for ﹤0.01% of the portfolio, ranked #5421.

Jeff Yass first reported a position in TNGX in Q4 2021 and has held it in 17 quarters since. 246 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Jeff Yass held 105,985 shares of Tango Therapeutics worth $3.31M as of Q2 2026.
  • Jeff Yass bought 19,635 Tango Therapeutics shares in Q2 2026, an estimated $485K.
  • Tango Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5421 holding.
  • Jeff Yass first reported a position in Tango Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • 246 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.